Clinical Trials Logo

Clinical Trial Summary

To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03441568
Study type Interventional
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+)1-888-84 22937
Email clinical-trials-contact@bayer.com
Status Not yet recruiting
Phase N/A
Start date September 7, 2018
Completion date November 16, 2018

See also
  Status Clinical Trial Phase
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis Phase 3
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Not yet recruiting NCT03632174 - Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis N/A
Not yet recruiting NCT03661138 - A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Phase 3
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2
Not yet recruiting NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT03559075 - Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
Recruiting NCT02910791 - The Role of Bacterial Toxins in Human Skin Disease N/A
Recruiting NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT02914548 - Study of OPA-15406 Ointment in Patients With Atopic Dermatitis Phase 2
Completed NCT02865356 - Topical Solution for the Treatment of Atopic Dermatitis Phase 2
Completed NCT02844452 - Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis N/A
Completed NCT02260986 - Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 3
Completed NCT01927705 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) Phase 1/Phase 2
Withdrawn NCT01936194 - The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis N/A
Recruiting NCT01692093 - KM110329 in Adult Patients With Atopic Dermatitis Phase 2
Terminated NCT01447758 - Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. Phase 1
Completed NCT02094287 - Placebo Effect in the Treatment of Atopic Dermatitis N/A
Completed NCT01179880 - A Study of E6005 in Japanese Patients With Atopic Dermatitis Phase 1/Phase 2
Completed NCT01223222 - A Study to Evaluate Safety, Tolerability and Efficacy of Lytixarâ„¢ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection Phase 2